Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives
Oslo, 15 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. For the first time all three product categories were above the NOK 100 million...
Dela artikeln
Taggar: navamedic, marked, records
Läs vidare på Dagens IndustriRelaterade nyheter
- Navamedic ASA: Renewed contract signed with Vitaflo International Limited
- Navamedic ASA: Record high quarter with above 50 percent growth
- Navamedic ASA: Significant growth across the business
- Navamedic tar hand om folkhälsan och går mot fortsatt tillväxt ⎮ #Investtalks
- Navamedic ASA Q1 2023: Another strong quarter
Fler ekonominyheter
- Navamedic ASA: Renewed contract signed with Vitaflo International Limited
- Navamedic ASA: Record high quarter with above 50 percent growth
- Navamedic ASA: Significant growth across the business
- Navamedic tar hand om folkhälsan och går mot fortsatt tillväxt ⎮ #Investtalks
- Navamedic ASA Q1 2023: Another strong quarter